What is the mechanism of action of neostigmine in the management of muscle paralysis?

• A. Inhibit acetylcholinesterase
• B. Stimulate presynaptic receptors
• C. Block sodium channels
• D. Increase serotonin availability

Answer: (A)

Neostigmine is a medication that works primarily by inhibiting acetylcholinesterase, an enzyme that breaks down acetylcholine in the synaptic cleft. By inhibiting this enzyme, neostigmine increases the concentration of acetylcholine at the neuromuscular junction. This elevation of acetylcholine enhances its action on muscle nicotinic receptors, facilitating greater muscular contraction and addressing muscle paralysis effectively.

This mechanism is particularly useful in conditions where muscle weakness occurs due to impaired transmission at the neuromuscular junction, such as in myasthenia gravis or as a reversal agent for non-depolarizing neuromuscular blockers used during anesthesia. By preventing the breakdown of acetylcholine, neostigmine enables stronger and more sustained muscle contractions, thereby alleviating paralysis.

The other options involve mechanisms that are not directly related to the action of neostigmine. Neostigmine does not stimulate presynaptic receptors, block sodium channels, or increase serotonin availability to exert its effects on muscle paralysis. Instead, its therapeutic action is focused on prolonging the activity of acetylcholine at the neuromuscular junction through its inhibition of acetylcholinesterase.